Detalhe da pesquisa
1.
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study.
Rheumatology (Oxford);
62(6): 2122-2129, 2023 06 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36282537
2.
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.
Ann Rheum Dis;
81(3): 351-358, 2022 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34815219
3.
Work productivity and activity impairment in patients with primary Sjögren's syndrome.
Clin Exp Rheumatol;
39 Suppl 133(6): 93-99, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34796845
4.
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial.
Rheumatol Ther;
11(3): 633-648, 2024 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38498139
5.
Sociodemographic and clinical factors associated with poor COVID-19 outcomes in patients with rheumatic diseases: data from the SAR-COVID Registry.
Clin Rheumatol;
42(2): 563-578, 2023 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36201124
6.
Primary Sjögren syndrome and development of another autoimmune rheumatic disease during the follow-up.
Adv Rheumatol;
62(1): 19, 2022 06 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35672809
7.
Primary Sjögren syndrome and development of another autoimmune rheumatic disease during the follow-up
Adv Rheumatol;
62: 19, 2022. tab, graf
Artigo
em Inglês
|
LILACS-Express
| ID: biblio-1383509
8.
Características clínicas y evolución de la infección por SARS-CoV-2 en pacientes con lupus eritematoso sistémico en Argentina: datos del registro nacional SAR-COVID / Clinical characteristics and course of SARS-CoV-2 infection in patients with systemic lupus erythematosus in Argentina: data from the SAR-COVID national registry
Rev. argent. reumatolg. (En línea);
33(4): 188-198, oct. 2022. tab, graf
Artigo
em Espanhol
| LILACS
| ID: biblio-1449423
9.
Expresión clínica del Síndrome de Sjögren primario en pacientes adultos diagnosticados a edad menor o igual a 35 años versus mayores de 35 años / Clinical expression of primary Sjögren's syndrome in adult patients diagnosed at an age less than or equal to 35 years versus those older than 35 years
Rev. argent. reumatolg. (En línea);
32(2): 16-19, jun. 2021. tab
Artigo
em Espanhol
| LILACS
| ID: biblio-1365487
10.
Manifestaciones cutáneas extraglandulares en pacientes con síndrome de Sjögren primario / Extraglandular cutaneous manifestations in patients with primary Sjögren's syndrome
Rev. colomb. reumatol;
25(2): 79-84, abr.-jun. 2018. tab
Artigo
em Espanhol
| LILACS
| ID: biblio-990931